Table 3 The downstream effects of the upstream regulators from the comparison of Vm vs. Vp.
From: Combating viral contaminants in CHO cells by engineering innate immunity
Virus | Consis-tency score | Total nodes (TF, TG, BP)*a | Transcription factors (TF) *b | Target genes (TG)*c | Biological Process (BP)*d | Relations*e |
|---|---|---|---|---|---|---|
VSV | 8.00 | 22 (4, 15, 3) | STAT1, IRF3, IRF5, IRF7 | CXCL10, DDX58, EIF2AK2, IFIH1, IL15, ISG15, JUN, Mx1/Mx2, OASL2, PSMB10, PSMB8, PSMB9, SOCS1, TAP1, TNFSF10 | Inhibit Replication of virus; Quantity of lesion. Activate Quantity of CD8+ T lymphocyte. | 2/12 (17%) |
EMCV | 12.16 | 29 (6, 19, 4) | STAT1, IRF3, IRF5, IRF7, TRIM24, ATF4 | BST2, CXCL10, DDX58, EIF2AK2, EIF4EBP1, IFIH1, IL15, ISG15, Mx1/Mx2, OASL2, PSMB10, PSMB8, PSMB9, SLC1A5, SLC3A2, SLC6A9, SLC7A5, TAP1, TNFSF10 | Inhibit Replication of virus; Transport of amino acids. Activate Quantity of CD8+ T lymphocyte; Quantity of MHC Class I on cell surface. | 3/24 (13%) |
EMCV | 7.91 | 18 (2, 10, 6) | CCND1, SMAD4 | AREG, CCND2, EREG, GJA1, HSPA8, ITGAV, NFKBIA, PTGS2, SOX4, SPP1 | Inhibit Arthritis; Cell cycle progression; Cell viability; Growth of ovarian follicle; Proliferation of cells. Activate Edema. | 7/12 (58%) |
EMCV | 6.96 | 19 (2, 10, 7) | MKL1, VDR | CAMP, CCL2, HLA-A, ICAM1, IL6, MMP9, PTGS2, RELB, SPP1, TNC | Inhibit Cancer; Quantity of interleukin; Rheumatic Disease; Development of body trunk. Activate Cell death of connective tissue cells; Nephritis; Organismal death. | 7/14 (50%) |
Reo-3 | 5.61 | 21 (4, 14, 3) | GFI1, NR1H3, NRIP1, PPARG | ACACB, CAV1, CD36, CSF3, ETS1, ID2, IL6, LDLR, LPL, NFKBIA, PDK2, PDK4, PPARA, SLC2A1 | Inhibit Oxidation of carbohydrate; Production of leukocytes; Quantity of vldl triglyceride in blood. | 1/12 (8%) |